Technical, economic, and clinical challenges to the development of new biomaterials-based vaccines
Name
64391658-MIT.pdf
Description
Full printable version
Size
5.94 MB
Format
Adobe PDF
Checksum (MD5)
81faee81a5147ebd115a2b98728da53a
Author(s)
Huffman, Kathleen Renee
Advisor(s)
Darrell J. Irvine.
Date Issued
2005
Publisher
Massachusetts Institute of Technology
Abstract
Research into novel vaccine methods is becoming increasingly important for the potential treatment of widespread diseases such as cancer, HIV, and malaria. Members of the Irvine laboratory have developed a hydrogel and particle-based injectable vaccine with the potential to treat such diseases. The vaccine aims to elicit a tailored immune response to a particular type of disease so as to destroy infected or cells in the body and/or develop immunological memory for future protection against the disease. The purpose of this paper is to analyze the feasibility of getting such a biomaterials-based novel vaccination method to the market. Topics such as application potential, efficacy, modes of delivery, storage, patent ability, and costs for producing the vaccine are explored. Finally, a suggested business strategy is outlined, through which value can be successfully obtained from the novel vaccine.
Description
Thesis (M. Eng.)--Massachusetts Institute of Technology, Dept. of Materials Science and Engineering, 2005.
Includes bibliographical references (leaves 81-87).
Subjects
Materials Science and Engineering.
MIT Department
Massachusetts Institute of Technology. Department of Materials Science and Engineering
Terms of Use
M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.
Persistent DSpace Link
